Maraviroc

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypertriglyceridemia

Conditions

Hypertriglyceridemia

Trial Timeline

Jan 1, 2011 → Nov 1, 2012

NCT ID

NCT01133210

About Maraviroc

Maraviroc is a phase 1 stage product being developed by Pfizer for Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01133210. Target conditions include Hypertriglyceridemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (16)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02934022	Pre-clinical	Completed	Jun 1, 2012	Dec 1, 2014	HIV Infection
NCT01384682	Approved	Completed	Aug 1, 2011	Dec 1, 2015	HIV
NCT01276236	Phase 2	Completed	Mar 9, 2011	Apr 30, 2015	Kaposi's Sarcoma
NCT01133210	Phase 1	Completed	Jan 1, 2011	Nov 1, 2012	Hypertriglyceridemia
NCT00944541	Phase 2	Completed	Sep 1, 2009	Jan 1, 2011	HIV Infection
NCT00982878	Phase 1	Completed	Sep 1, 2009	Feb 1, 2011	HIV Infections
NCT00801515	Pre-clinical	Completed	Aug 1, 2009	Jul 1, 2011	HIV
NCT00850395	Pre-clinical	Completed	Jul 1, 2009	Oct 1, 2011	HIV-1
NCT00791700	Phase 2	UNKNOWN	Apr 22, 2009	Jun 30, 2023	Human Immunodeficiency Virus
NCT00925756	Approved	Completed	Oct 20, 2008	Apr 11, 2014	HIV Infections
NCT00719823	Phase 3	Withdrawn	Aug 1, 2008	May 1, 2010	Human Immunodeficiency Virus Type 1
NCT00775294	Phase 1	Completed	May 1, 2008	Mar 1, 2010	HIV/AIDS
NCT00795444	Phase 2	Completed	Mar 1, 2008	Jan 1, 2015	HIV-1
NCT00703586	Phase 1	Completed	Sep 1, 2007	May 1, 2011	HIV Infections
NCT00478231	Phase 3	Completed	Jul 1, 2007	Sep 1, 2010	Acquired Immunodeficiency Syndrome
NCT00496782	Phase 1	Terminated	Jul 1, 2007	Oct 1, 2008	HIV Infections

Competing Products

20 competing products in Hypertriglyceridemia

See all competitors

Product	Company	Stage	Hype Score
LY3875383 + Placebo	Eli Lilly	Phase 1	33
ZYH7 + ZYH7 + ZYH7 + Fenofibrate	Zydus Lifesciences	Phase 2	52
Solbinsiran + Placebo	Eli Lilly	Phase 2	52
Placebo + Ethyl Icosapentate	Sumitomo Pharma	Phase 3	77
Omega-3-Acid Ethyl Esters 90 Soft Capsules + Corn Oil	Jiangsu Hengrui Medicine	Phase 3	77
warfarin + omefas + omega-3-acid ethyl esters	AstraZeneca	Phase 1	33
rosuvastatin	AstraZeneca	Approved	85
Simvastatin + acetylsalicylic acid (ASA) + omefas	AstraZeneca	Phase 1	33
Olive oil, 4g + omega-3-carboxylic acids, 2g + omega-3-carboxylic acids, 4g	AstraZeneca	Phase 3	77
Epanova (4 g) and Lovaza (4 g) + Lovaza (4 g) and Epanova (4 g)	AstraZeneca	Phase 2	52
rosuvastatin 40 mg tablet + Epanova™ QD (2 x 1 g capsules) + Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose + Multiple (20) oral doses of 2 g Vascepa® every 12 hours	AstraZeneca	Phase 1	33
placebo + omefas + omefas + omefas	AstraZeneca	Phase 2/3	65
Epanova + Lovaza	AstraZeneca	Phase 1	33
Epanova + Olive Oil	AstraZeneca	Phase 3	77
AZD0585 + AZD0585 placebo	AstraZeneca	Phase 3	77
ABT-143 + simvastatin	AstraZeneca	Phase 3	77
torcetrapib/atorvastatin + atorvastatin	Pfizer	Phase 3	76
Icosapent (MND-2119) + Icosapent (EPADEL CAPSULES 300)	Mochida Pharmaceutical	Phase 3	76
Icosapent	Mochida Pharmaceutical	Phase 3	76
REGN1500 + placebo	Regeneron Pharmaceuticals	Phase 1	32

Other Products from Pfizer